Specifically, SSX mRNA was expressed in 75% of synovial sarcoma, 57% of head and neck cancer, 55% of bladder cancer, 50% of ovarian cancer, 43% of malignant melanoma, 40% of prostate cancer, 36% of nonHodgkin's lymphoma, 33% of stomach cancer, 27% of colorectal cancer, 21% of breast cancer, 21% of lung, 16% of glioma, 13% of endometrial, and 4% of renal cell carcinoma tissues (Table 2). Here, SSX2 is linked to melanoma.